Clinical trials: Anemia, completed
Aplastic Anemia
Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects
This was an open label, non-randomized, phase II study of eltrombopag in combination with rabbit ATG/CsA in subjects with moderate or more severe AA who did not received prior ATG/ALG-based immunosuppressive therapy.
- Trial name
- NCT02404025
- Testing
- Eltrombopag, Rabbit ATG, CsA
- Where
- 11 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Anemia
Darbepoetin Alfa Treatment of Anemia in Hemodialysis Subjects
The purpose of this study is to compare once a week and once every other week darbepoetin alfa on the change in hemoglobin levels between the screening/baseline period and the evaluation period (weeks 25-30).
- Trial name
- NCT00119587
- Testing
- darbepoetin alfa
- Sponsor
- Amgen
Thalassemia
A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-Thalassemia
This is a Phase 2, double-blind, randomized, placebo-controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) versus placebo in adults with non-transfusion dependent beta (β)-thalassemia.
- Trial name
- BEYOND (NCT03342404)
- Testing
- Luspatercept, Best Supportive Care (BSC)
- Where
- 16 sites in United States, Greece and 4 more
- Volunteers
- 145 people
- Sponsor
- Celgene
Chronic Myeloproliferative Disorders, Leukemia
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
RATIONALE: Donor peripheral stem cell transplantation may be able to replace bone marrow and immune cells that were destroyed by chemotherapy. Sometimes the transplanted cells from a donor are rejected by the body's normal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00080925
- Testing
- filgrastim, graft-versus-tumor induction therapy, rituximab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Thalassemia Major (TM), Thalassemia Intermedia (TI)
Beta-thalassemia and Microparticles
The results will allow us to evaluate the role of MP in the thrombo-embolic risk observed in thalassemic patients and to underline a possible difference between TM and TI.
- Conditions
- Thalassemia Major (TM), Thalassemia Intermedia (TI), Microparticles (MP)Originating From Platelets, Endothelial Cells and Monocytes
- Trial name
- NCT01284738
- Testing
- Physiopathology
- Where
- France
- Volunteers
- 33 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Sickle Cell Disease, Sickle Cell
Objective Neurocognitive Assessment of Young Children With Sickle Cell Disease by Eye-Tracking
Evidence indicates that Sickle Cell Disease (SCD) threatens neurodevelopmental outcome. Although children with SCD may be heterogeneously affected, neurocognitive impairment may already be present in toddlers.
- Conditions
- Sickle Cell Disease, Sickle Cell, Neurocognition, Child
- Trial name
- ONSET (NCT07721155)
- Testing
- eyetracking, blood work, Strengths and difficulties questionnaire (SDQ)
- Where
- Netherlands
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Iron Deficiency, Anaemia
Bioequivalence Study of Ferric Carboxymaltose Injection in Participants With Iron Deficiency Anaemia
The goal of this clinical trial is to compare the pharmacokinetic profile of the developed drug product and reference product in participants with iron deficiency anaemia under fasting condition.
- Trial name
- NCT06080555
- Testing
- Ferric Carboxymaltose Injection, Ferric Carboxymaltose Injection [Ferinject]
- Where
- 4 sites in China
- Volunteers
- 84 people
- Sponsor
- Sichuan Huiyu Pharmaceutical Co., Ltd
Iron Deficiency Anemia, Iron Deficiency Anaemia
An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)
Evaluate safety and efficacy of intravenous (IV) iron isomaltoside/ferric derisomaltose re-dosing, in subjects who were previously treated with iron isomaltoside/ferric derisomaltose.
- Trial name
- FERWON-EXT (NCT02962648)
- Testing
- Iron isomaltoside/ferric derisomaltose
- Where
- 22 sites in United States
- Volunteers
- 103 people
- Sponsor
- Pharmacosmos A/S
Iron Deficiency Anemia, Obscure Gastrointestinal Bleeding
Role of AI in CE for the Identification of SB Lesions in Patients With Small Intestinal Bleeding.
Capsule Endoscopy (CE) is a safe, patient friendly and easy procedure performed for the evaluation of gastrointestinal tract unable to be explored via conventional endoscopy.
- Trial name
- ArtIC (NCT04821349)
- Testing
- Capsule endoscopy
- Where
- Italy
- Volunteers
- 137 people
- Sponsor
- Fondazione Poliambulanza Istituto Ospedaliero
Anaemia
A Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)
Daprodustat is a drug that is currently being developed as a treatment for renal anemia . This study is to evaluate the efficacy and safety of daprodustat following a switch from erythropoiesis-stimulating agent (ESA) in Japanese…
- Trial name
- NCT02969655
- Testing
- Daprodustat small, Daprodustat large, Darbepoetin alfa
- Where
- 50 sites in Japan
- Volunteers
- 271 people
- Sponsor
- GlaxoSmithKline
Anemia, Sickle Cell
Effectiveness of Arginine as a Treatment for Sickle Cell Anemia
Sickle cell disease (SCD), also known as sickle cell anemia, is an inherited genetic disease that can cause intense pain episodes.
- Trial name
- Arginine (NCT00513617)
- Testing
- Arginine
- Where
- 17 sites in United States
- Volunteers
- 128 people
- Sponsor
- UCSF Benioff Children's Hospital Oakland
Sickle Cell Disease
Clinical Trial to Study the Safety and Tolerability of Memantin Mepha® in Sickle Cell Disease Patients
Symptomatic sickle cell disease is worldwide the most frequent cause for hereditary hemolytic anemia with recurrent pain crisis.
- Trial name
- MemSID (NCT02615847)
- Testing
- Memantinhydrochlorid
- Where
- Switzerland
- Volunteers
- 9 people
- Sponsor
- University of Zurich
Sickle Cell Anemia in Children
Effect of Aquatic Exercises on Muscle Strength and Quality of Life in Children With Sickle Cell Anemia
Sickle cell anemia is a global public health disorder that affects millions of people across the globe. It is an inherited autosomal recessive hemoglobin condition caused by a beta-globin gene mutation that results in an aberrant…
- Trial name
- NCT06939933
- Testing
- aquatic exercise in addition to physical exercise, designed physical exercises only
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Kafrelsheikh University
Vaso-occlusive Crisis, Sickle Cell Disease
Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC)
The purpose of this study is to evaluate whether MST-188 can reduce the duration of vaso-occlusive crisis (VOC) in subjects with sickle cell disease.
- Trial name
- EPIC (NCT01737814)
- Testing
- Saline, MST-188
- Where
- 72 sites in United States, Belgium and 9 more
- Volunteers
- 388 people
- Sponsor
- Mast Therapeutics, Inc.
Vitamin D Deficiency, Stem Cell Transplant Complications
A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT
Research has suggested that children with sufficient vitamin D levels undergoing hematopoietic stem cell transplant (HSCT) have improved outcomes, including lower incidences of infection and graft-versus-host disease (GVHD), as…
- Conditions
- Vitamin D Deficiency, Stem Cell Transplant Complications, Pediatric Cancer, Blood Disorder
- Trial name
- NCT03176849
- Testing
- Vitamin D3, Standard Vitamin D3 Supplementation
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Phoenix Children's Hospital
Ovarian Cancer, Hereditary Ovarian Cancer Syndrome
C-PATROL - Non-interventional Study (NIS) to Collect Clinical and Patient Reported Outcome Data in an Olaparib Treated BRCAm+ PSR Ovarian Cancer Population
The main objective of the proposed non-interventional study is to obtain real-world effectiveness, safety and treatment patterns data of patients with BRCAm+ (Breast Cancer Gene(s) mutation positive) platinum sensitive relapsed…
- Trial name
- C-PATROL (NCT02503436)
- Where
- 68 sites in Germany
- Volunteers
- 276 people
- Sponsor
- AstraZeneca
Sickle Cell Disease
A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease
This is an open label, multicenter, Phase 1/2 study in approximately eight adults with severe Sickle Cell Disease (SCD). The study will evaluate the safety, tolerability, and efficacy of autologous hematopoietic stem cell…
- Trial name
- NCT03653247
- Testing
- Plerixafor, Busulfan, BIVV003
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- Sangamo Therapeutics
Iron Deficiencies
Efficacy Evaluation of an ODF Iron Supplement Vs an Iron Supplement in Capsules in Subjects with Mild Anemia
The aim of the study is to evaluate the efficacy of a new iron supplement with orodispersible formulation vs an iron supplement in capsules in subjects with mild anemia.
- Trial name
- NCT05989984
- Testing
- ODF Iron Supplement, Iron Supplement in Capsules
- Where
- Italy
- Volunteers
- 23 people
- Sponsor
- IBSA Farmaceutici Italia Srl
Anemia
An Observational Study of Mircera in Renal Anemia Correction In Dialysed Patients During Daily Clinical Practice
This observational, multi-center study will evaluate the efficacy and safety of Mircera (methoxy polyethylene glycol-epoetin beta) in renal anemia correction in dialysed patients in daily clinical practice.
- Trial name
- NCT01690455
- Where
- 33 sites in Poland
- Volunteers
- 247 people
- Sponsor
- Hoffmann-La Roche
Kidney Disease
An Evaluation of Aranesp® in Subjects With Anaemic Chronic Kidney Disease (CKD)
The purpose of this study is to assess if Aranesp® administered once every 4 weeks to chronic kidney disease subjects is safe and efficacious in maintaining haemoglobin levels greater than or equal to 100 g/L.
- Trial name
- NCT00124098
- Testing
- Aranesp® (darbepoetin alfa)
- Sponsor
- Amgen